

Biobehavioral and Behavioral Processes 3. Language and Communication (LCOM).

*Date:* February 20–21, 2003.

*Time:* 8:30 a.m. to 6 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Holiday Inn Georgetown, 2101 Wisconsin Avenue, NW., Washington, DC 20007.

*Contact Person:* Weijia Ni, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3190, MSC 7848, (for overnight mail use room # and 20817 zip), Bethesda, MD 20892. (301) 435–1507. [niw@csr.nih.gov](mailto:niw@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Behavioral Medicine: Interventions and Outcomes.

*Date:* February 20–21, 2003.

*Time:* 8:30 a.m. to 6 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* George Washington University Inn, 824 New Hampshire Ave., NW., Washington, DC 20037.

*Contact Person:* Lee S. Mann, PhD, JD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3186, MSC 7848, Bethesda, MD 20892. (301) 435–0677.

*Name of Committee:* Cell Development and Function Integrated Review Group, International and Cooperative Projects Study Section.

*Date:* February 20–21, 2003.

*Time:* 8:30 a.m. to 2:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* The Fairmont, 2401 M Street, Washington, DC 20037.

*Contact Person:* Sandy Warren, DMD, MPH, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5134, MDC 7840, Bethesda, MD 20892. (301) 435–1019.

*Name of Committee:* Biophysical and Chemical Sciences Integrated Review Group, Bio-Organic and Natural Products Chemistry Study Section.

*Date:* February 20–21, 2003.

*Time:* 8:30 a.m. to 6 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Holiday Inn Georgetown, 2101 Wisconsin Avenue, NW., Washington, DC 20007.

*Contact Person:* Mike Radtke, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4176, MSC 7806, Bethesda, MD 20892. (301) 435–1728. [rادتke@csr.nih.gov](mailto:rادتke@csr.nih.gov).

*Name of Committee:* Integrative, Functional and Cognitive Neuroscience Integrated Review Group, Integrative, Functional and Cognitive Neuroscience 7.

*Date:* February 20–21, 2003.

*Time:* 8:30 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* One Washington Circle, 1 Washington Circle, NW., Washington, DC 20037.

*Contact Person:* Bernard F. Driscoll, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5158, MSC 7844, Bethesda, MD 20892. (301) 435–1242.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Epidemiology of Clinical Disorders and Aging.

*Date:* February 20–21, 2003.

*Time:* 8:30 a.m. to 4 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* Mary Ann Guadagno, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1104, MSC 7780, Bethesda, MD 20892. (301) 435–8011.

*Name of Committee:* Cell Development and Function Integrated Review Group, Cell Development and Function 1.

*Date:* February 20–21, 2003.

*Time:* 8:30 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hilton Washington Embassy Row, 2015 Massachusetts Ave., NW., Washington, DC 20036.

*Contact Person:* Michael H. Sayre, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5128, MSC 7840, Bethesda, MD 20892. (301) 435–1219. [sayrem@csr.nih.gov](mailto:sayrem@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Complement and SLE.

*Date:* February 20, 2003.

*Time:* 12:15 p.m. to 1:15 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Telephone conference call.)

*Contact Person:* George W. Chacko, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6707 Rockledge Drive, Room: 4202, MSC: 7812, Bethesda, MD 20892, (301) 435–1220. [chackoge@csr.nih.gov](mailto:chackoge@csr.nih.gov).

*Name of Committee:* Social Sciences, Nursing, Epidemiology and Methods Integrated Review Group, Social Sciences, Nursing, Epidemiology and Methods 5.

*Date:* February 21, 2003.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hilton Washington Embassy Row, 2015 Massachusetts Avenue, NW., Washington, DC 20036.

*Contact Person:* Ann Hardy, DRPH, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3158, MSC 7770, Bethesda, MD 20892. (301) 435–0695. [hardyan@csr.nih.gov](mailto:hardyan@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Innate Immunity/Host Defense.

*Date:* February 21, 2003.

*Time:* 8:30 a.m. to 4:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* The River Inn, 924 Twenty-Fifth Street, NW., Washington, DC 20037.

*Contact Person:* Calbert A. Laing, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4210, MSC 7812, Bethesda, MD 20892. (301) 435–0695. [laingc@csr.nih.gov](mailto:laingc@csr.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine, 93.306; 93.333, Clinical Research, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: January 29, 2003.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 03–2609 Filed 2–4–03; 8:45 am]

**BILLING CODE 4140–01–M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of Exclusive License: “Interleukin-2 Receptor and Applications Thereof”

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the inventions embodied in U.S. Patent No. 5,833,983, entitled “Interleukin-2 Receptor and Applications Thereof,” to Celltech R&D Ltd., a non-U.S. company with headquarters in the United Kingdom.

The prospective exclusive license territory may be worldwide and the field of use may be therapeutics for the treatment of inflammatory diseases.

**DATES:** Only written comments and/or license applications which are received by the National Institutes of Health on or before April 7, 2003 will be considered.

**ADDRESSES:** Requests for copies of the patent, inquiries, comments and other materials relating to the contemplated exclusive license should be directed to: Matthew B. Kiser, Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804. Telephone:

(301) 435-5236; Facsimile (301) 402-0220; E-mail [kiserm@od.nih.gov](mailto:kiserm@od.nih.gov).

**SUPPLEMENTARY INFORMATION: U.S.**

Patent No. 5,833,983 relates to the field of receptor molecules. Specifically, the technology is related to a new polypeptide receptor for interleukin-2, which is a component of the high affinity IL-2 receptor, antibodies against this new polypeptide and recombinant interleukins capable of binding to the new receptor.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, the NIH receives written evidence and argument that establish that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: January 28, 2003.

**Jack Spiegel,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer.*  
[FR Doc. 03-2625 Filed 2-4-03; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### **Prospective Grant of Exclusive License: "Spatially and Temporal Control of Gene Expression Protein Promoter in Combination with Local Heat"**

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the inventions embodied in International Patent Application No. PCT/US97/15270, entitled "Spatially and Temporal Control of Gene Expression Protein Promoter in Combination with Local

Heat," to Celsion Corporation, a US company with headquarters in Maryland.

The prospective exclusive license territory may be worldwide and the field of use may be limited to gene-based therapeutics for the treatment of cancer.

**DATES:** Only written comments and/or license applications which are received by the National Institutes of Health on or before April 7, 2003 will be considered.

**ADDRESSES:** Requests for copies of the patent, inquiries, comments and other materials relating to the contemplated exclusive license should be directed to: Matthew B. Kiser, Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804. Telephone: (301) 435-5236; Facsimile (301) 402-0220; E-mail [kiserm@od.nih.gov](mailto:kiserm@od.nih.gov).

**SUPPLEMENTARY INFORMATION:**

International Patent Application No. PCT/US97/15270 relates to the spatial and temporal control of exogenous gene expression in genetically engineered cells and organisms. In particular, it discloses the use of heat inducible promoters, such as the promoter of heat shock genes to control the expression of exogenous genes. It further relates to the use of focused ultrasound to heat cells that contain therapeutic genes under the control of heat shock promoters, thereby inducing the expression of therapeutic genes.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, the NIH receives written evidence and argument that establish that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: January 28, 2003.

**Jack Spiegel,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer.*  
[FR Doc. 03-2624 Filed 2-4-03; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-4572-D-31]

### **Order of Succession for the Office of Housing**

**AGENCY:** Office of the Assistant Secretary for Housing, HUD.

**ACTION:** Notice of Order of Succession.

**SUMMARY:** In this notice, the Assistant Secretary for Housing designates the Order of Succession for the Office of Housing. This Order of Succession supersedes the Order of Succession for the Assistant Secretary for Housing, published on August 22, 2000 (65 FR 51015).

**EFFECTIVE DATE:** January 27, 2003.

**FOR FURTHER INFORMATION CONTACT:** Eliot C. Horowitz, Senior Advisor to the Assistant Secretary for Housing—Federal Housing Commissioner, Office of Housing, Department of Housing and Urban Development, 451 Seventh Street, SW., Room 9110, Washington, DC 20410-0500. Telephone (202) 708-1490 (this is not a toll-free number). A telecommunications device for hearing- and speech-impaired persons (TTY) is available at 1-800-877-9339 (Federal Information relay Service) (this is a toll-free number).

**SUPPLEMENTARY INFORMATION:** The Assistant Secretary for Housing is issuing this Order of Succession of officials authorized to perform the functions and duties of the Office of the Assistant Secretary for Housing when, by reason of absence, disability, or vacancy in office, the Assistant Secretary is not available to exercise the powers or perform the duties of the office. This Order of Succession is subject to the provisions of the Vacancy Reform Act of 1998, 5 U.S.C. 3345-3349d. This publication supersedes the Order of Succession notice published on August 22, 2000, at 65 FR 51015.

Accordingly, the Assistant Secretary for Housing designates the following Order of Succession:

#### **Section A. Order of Succession**

Subject to the provisions of the Vacancy Reform Act of 1998, during any period when, by reason of absence, disability, or vacancy in office, the Assistant Secretary for Housing is not available to exercise the powers or perform the duties of the Office of Assistant Secretary for Housing, the following officials within the Office of Housing are hereby designated to exercise the powers and perform the duties of the Office: